MedWatch

GN Hearing will grow by 5–10 percent in 2022

On Thursday, GN Hearing has released its full-year figures for 2021 and its 2022 outlook. The hearing aid manufacturer expects to grow organically by 5–10 percent with an EBITA margin of 14 percent in the current financial year.

Photo: GN Store Nord / PR

On Thursday morning, hearing aid manufacturer GN Hearing has released its full-year figures for 2021 and in connection with the report comes the company’s 2022 outlook.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs